-
Mar 14, 2024 | 
mondaq.com | Diane Hazel |Benjamin Dryden |Kate E. Gehl
The U.S. Federal Trade Commission (FTC) recently published a blog post warning that the use of algorithms
to assist in determining prices may violate federal antitrust laws,
regardless of the business or industry. The FTC blog references a
Statement of Interest that it and the U.S. Department of Justice
(DOJ) (together, the Agencies) filed earlier that same day in
Duffy v. Yardi Systems, Inc. in the Western District of
Washington.
-
Mar 7, 2024 | 
jdsupra.com | Benjamin Dryden |Kate E. Gehl |Elizabeth Haas
The U.S. Federal Trade Commission (FTC) recently published a blog post warning that the use of algorithms to assist in determining prices may violate federal antitrust laws, regardless of the business or industry. The FTC blog references a Statement of Interest that it and the U.S. Department of Justice (DOJ) (together, the Agencies) filed earlier that same day in Duffy v. Yardi Systems, Inc. in the Western District of Washington.
-
Nov 27, 2023 | 
natlawreview.com | Kate E. Gehl
The Federal Trade Commission (FTC) recently submitted a comment to the U.S. Copyright Office in response to its “Notice of Inquiry” in the Federal Register examining copyright issues related to artificial intelligence (AI). The FTC’s comment focuses largely on potential threats to competition from AI and potential unfair copyright practices involving AI.
-
Nov 22, 2023 | 
mondaq.com | Kate E. Gehl |David Rosen |Stephen B. Maebius
The listing of many types of patents in the FDA's Orange Book (Approved Drug Products
with Therapeutic Equivalence Evaluations) is fairly
straightforward. Patents covering the approved drug product (active
pharmaceutical ingredient) or its methods of use can be listed.
-
Nov 17, 2023 | 
natlawreview.com | Kate E. Gehl
The listing of many types of patents in the FDA’s Orange Book (Approved Drug Products with Therapeutic Equivalence Evaluations) is fairly straightforward. Patents covering the approved drug product (active pharmaceutical ingredient) or its methods of use can be listed.
-
Sep 18, 2023 | 
jdsupra.com | Courtenay C. Brinckerhoff |Kate E. Gehl
As announced in a September 14, 2023, press release, the FTC has issued a policy statement “warning pharmaceutical companies that make and sell brand-name drugs that they could face legal action if they improperly list patents in the FDA’s [Orange Book].” The policy statement builds on the premise that “[b]rand drug manufacturers may be harming generic competition through the improper listing of patents” in the Orange Book, and warns that the “FTC intends to use its full legal authority to...
-
Apr 26, 2023 | 
jdsupra.com | Benjamin Dryden |Kate E. Gehl
AI in Health Care Series: Article 3Health care companies are increasingly using artificial intelligence (AI) to create innovations, set prices, and compete with rivals. At the same time, federal and state antitrust enforcers are finding new ways to apply antitrust law to the modern, data-driven economy. Amid these myriad changes in technology and the law, the time is ripe to consider what the growth of AI in health care means for antitrust compliance.
-
Apr 25, 2023 | 
lexblog.com | Benjamin Dryden |Kate E. Gehl
Health care companies are increasingly using artificial intelligence (AI) to create innovations, set prices, and compete with rivals. At the same time, federal and state antitrust enforcers are finding new ways to apply antitrust law to the modern, data-driven economy. Amid these myriad changes in technology and the law, the time is ripe to consider what the growth of AI in health care means for antitrust compliance.
-
Mar 30, 2023 | 
jdsupra.com | Kate E. Gehl |Elizabeth Haas
Foley Forward: Trends 2023Manufacturing companies should actively prepare for heightened antitrust scrutiny of their business practices in 2023, including practices that have not traditionally garnered the focus of the federal antitrust enforcers. Employee noncompetes have recently come under fire from the Federal Trade Commission (FTC).
-
Mar 29, 2023 | 
natlawreview.com | Kate E. Gehl
Wednesday, March 29, 2023 Manufacturing companies should actively prepare for heightened antitrust scrutiny of their business practices in 2023, including practices that have not traditionally garnered the focus of the federal antitrust enforcers. Employee noncompetes have recently come under fire from the Federal Trade Commission (FTC).
